Expression of IL-27 by Tumor Cells in InvasCutaneous and Metastatic Melanomas

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Gonin, Julie ^a,b   Carlotti, Agnès ^b   Dietrich, Céline ^a   Audebourg, Anne ^b   Radenen Bussière, Brigitte ^b   Caignard, Anne ^c   Avril, Marie Françoise ^d   Vacher Lavenu, Marie Cécile ^b   Larousserie, Frédérique ^a,b   Devergne, Odile ^a  

^a CNRS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 27; PROGRAMMED DEATH 1 LIGAND 1;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; CORRELATION ANALYSIS; CUTANEOUS MELANOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MELANOMA CELL; METASTASIS; NEVUS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIGENS, CD274; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; INTERLEUKIN-27; MELANOMA; NEVUS, PIGMENTED;

EID: 84885392212     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075694     Document Type: Article

References (47)

1. Ko JM, Fisher DE, (2011) A new era: melanoma genetics and therapeutics. J Pathol 223: 241-250.
2. Nagai H, Oniki S, Fujiwara S, Yoshimoto T, Nishigori C, (2010) Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy 2: 697-709.
3. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, et al. (2010) Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol pii: 832454.
4. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, et al. (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70: 1143-1153.
5. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, et al. (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16: 779-790.
6. Hunter CA, Kastelein R, (2012) Interleukin-27: balancing protective and pathological immunity. Immunity 37: 960-969.
7. Morishima N, Mizoguchi I, Okumura M, Chiba Y, Xu M, et al. (2010) A pivotal role for interleukin-27 in CD8+ T cell functions and the generation of cytotoxic T lymphocytes. J Biomed Biotechnol 2010: 605483.
8. Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, et al. (2005) Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol 175: 1686-1693.
9. Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N, (2011) IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol 41: 47-59.
10. Matsui M, Moriya O, Belladonna ML, Kamyia S, Lemonnier FA, et al. (2004) Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J Virol 78: 9093-9104.
11. Zhu S, Lee DA, Li S, (2010) IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184: 2348-2354.
12. Hisada M, Kamiya S, Fujita K, Belladona ML, Aoki T, (2004) Potent antitumor activity of interleukin-27. Cancer Res 64: 1152-1156.
13. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, et al. (2005) Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 115: 427-442.
14. Ho M-Y, Leu S-JJ, Sun G-H, Tao M-H, Tang S-J, et al. (2009) IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 183: 6217-6226.
15. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, et al. (2004) IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 173: 7170-7182.
16. Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, et al. (2009) Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 182: 4328-4338.
17. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, et al. (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 66: 6395-6404.
18. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, et al. (2006) Antiangiogenic and antitumor activities of IL-27. J Immunol 176: 7317-7324.
19. Ho MY, Jim Leu SJ, Sun GH, Tao MH, Tang SJ, et al. (2009) IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 183: 6217-6226.
20. Mohr P, Eggermont AM, Hauschild A, Buzaid A, (2009) Staging of cutaneous melanoma. Ann Oncol 20Suppl 6: vi14-21.
21. Devergne O, Coulomb-L'Herminé A, Capel F, Moussa M, Capron F, (2001) Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol 159: 1763-1776.
22. Larousserie F, Pflanz S, Coulomb-L'Herminé A, Brousse N, Kastelein R, et al. (2004) Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 202: 164-171.
23. Larousserie F, Bardel E, Pflanz S, Arnulf B, Lome-Maldonado C, et al. (2005) Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol 166: 1217-1228.
24. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, et al. (2011) Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 17: 2628-2637.
25. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, et al. (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8: 1363-1371.
26. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, et al. (2007) Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 8: 1372-1379.
27. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, et al. (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8: 1380-1389.
28. Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE, et al. (2009) IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol 183: 2435-2443.
29. Javelaud D, Alexaki VI, Mauviel A, (2008) Transforming growth factor-ß in cutaneous melanoma. Pigement Cell Melanoma Res 21: 123-132.
30. Dummer W, Bastian BC, Ernst N, Schänzle C, Schwaaf A, et al. (1996) Interleukin-10 production in malignant melanoma: preferential detection of IL-10 secreting tumor cells in metastatic lesions. Int J Cancer 66: 607-610.
31. Itakura E, Huang R-R, Wen D-R, Paul E, Wünsch PH, et al. (2011) IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastic competence. Mod Pathol 24: 801-809.
32. Karakhanova S, Bedke T, Enk AH, Mahnke K, (2011) IL-27 renders DC immunosuppressive by induction of B7-H1. J Leukoc Biol 89: 837-845.
33. Hirahara K, Ghoreschi K, Yang X-P, Takahashi H, Laurence A, et al. (2012) Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 36: 1017-1030.
34. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, et al. (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116: 1757-1766.
35. Gadiot J, Hooijkaas AI, Kaiser ADM, van Tinteren H, van Boven H, et al. (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117: 2192-2201.
36. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, et al. (2011) IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol 186: 3977-3985.
37. Tanida S, Yoshitomi H, Ishikawa M, Kasahara T, Murata K, et al. (2011) IL-27-producing CD14(+) cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration. Cytokine 55: 237-244.
38. Niedobitek G, Pazolt D, Teichmann M, Devergne O, (2002) Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 198: 310-316.
39. Larousserie F, Bardel E, Coulomb-L'Herminé A, Canioni D, Brousse N, et al. (2006) Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas. J Pathol 209: 360-368.
40. Gonin J, Larousserie F, Bastard C, Picquenot JM, Couturier J, et al. (2011) Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma, PloS ONE, e24617.
41. Pradhan A, Lambert QT, Reuther GW, (2007) Transformation of hematopoietic cells and activation of Jak2-V617F by IL-27R, a component of a heterodimeric type 1 cytokine receptor. Proc Natl Acad Sci USA 104: 18502-18507.
42. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, et al. (2008) Antiproliferative activity of IL-27 on melanoma. J Immunol 180: 6527-6535.
43. Kalliolias GD, Ivashkiv LB, (2008) IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLR and p38. J Immunol 180: 6325-6333.
44. Coulomb-L'Herminé A, Larousserie F, Pflanz S, Bardel E, Kastelein R, et al. (2007) Expression of interleukin-27 by human trophoblast cells. Placenta 28: 1133-1140.
45. Guleria I, Sayegh MH, (2007) Maternal acceptance of the fetus: true human tolerance. J Immunol 178: 3345-3351.
46. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465.
47. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safetey, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.